BioTelemetry Inc (BEAT) Holdings Lowered by ETRADE Capital Management LLC

ETRADE Capital Management LLC trimmed its position in BioTelemetry Inc (NASDAQ:BEAT) by 4.6% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 32,454 shares of the medical research company’s stock after selling 1,556 shares during the quarter. ETRADE Capital Management LLC owned approximately 0.10% of BioTelemetry worth $1,008,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in the business. Schwab Charles Investment Management Inc. boosted its holdings in shares of BioTelemetry by 5.3% in the first quarter. Schwab Charles Investment Management Inc. now owns 148,109 shares of the medical research company’s stock worth $4,599,000 after buying an additional 7,475 shares during the period. Hood River Capital Management LLC boosted its holdings in shares of BioTelemetry by 1.3% in the first quarter. Hood River Capital Management LLC now owns 1,205,511 shares of the medical research company’s stock worth $37,431,000 after buying an additional 14,885 shares during the period. Psagot Investment House Ltd. acquired a new position in shares of BioTelemetry in the first quarter worth about $683,000. Swiss National Bank boosted its holdings in shares of BioTelemetry by 5.5% in the first quarter. Swiss National Bank now owns 53,600 shares of the medical research company’s stock worth $1,664,000 after buying an additional 2,800 shares during the period. Finally, Miles Capital Inc. acquired a new position in shares of BioTelemetry in the first quarter worth about $285,000. Institutional investors own 86.21% of the company’s stock.

BEAT stock opened at $41.20 on Friday. The company has a quick ratio of 1.83, a current ratio of 1.96 and a debt-to-equity ratio of 0.77. The company has a market cap of $1.34 billion, a P/E ratio of 37.09, a P/E/G ratio of 3.23 and a beta of 0.81. BioTelemetry Inc has a 52 week low of $40.35 and a 52 week high of $40.80.

BioTelemetry (NASDAQ:BEAT) last posted its quarterly earnings results on Wednesday, April 25th. The medical research company reported $0.39 EPS for the quarter, topping the consensus estimate of $0.23 by $0.16. The business had revenue of $94.50 million during the quarter, compared to analysts’ expectations of $91.55 million. BioTelemetry had a negative net margin of 3.13% and a positive return on equity of 16.63%. The firm’s quarterly revenue was up 69.1% compared to the same quarter last year. During the same period last year, the company posted $0.16 earnings per share. analysts anticipate that BioTelemetry Inc will post 1.26 earnings per share for the current year.

Several research analysts have commented on the stock. BidaskClub upgraded shares of BioTelemetry from a “hold” rating to a “buy” rating in a report on Tuesday, April 17th. Zacks Investment Research cut shares of BioTelemetry from a “hold” rating to a “sell” rating in a report on Thursday, February 8th. Benchmark reiterated a “buy” rating and issued a $46.00 target price (up from $44.00) on shares of BioTelemetry in a report on Thursday, April 26th. Finally, ValuEngine upgraded shares of BioTelemetry from a “hold” rating to a “buy” rating in a report on Friday, April 27th. Two research analysts have rated the stock with a sell rating, seven have issued a buy rating and one has issued a strong buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $43.29.

In related news, insider Fred Broadway sold 54,158 shares of the firm’s stock in a transaction that occurred on Tuesday, March 13th. The shares were sold at an average price of $34.17, for a total transaction of $1,850,578.86. Following the completion of the sale, the insider now directly owns 64,880 shares in the company, valued at $2,216,949.60. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP Peter Ferola sold 67,370 shares of the firm’s stock in a transaction that occurred on Friday, May 11th. The stock was sold at an average price of $40.42, for a total transaction of $2,723,095.40. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 263,503 shares of company stock valued at $10,153,267. 9.60% of the stock is currently owned by corporate insiders.

BioTelemetry Company Profile

BioTelemetry, Inc, a mobile and wireless medical technology company, provides cardiac and mobile blood glucose monitoring (BGM), centralized medical imaging, and original equipment manufacturing services for the healthcare and clinical research industries. It operates in three segments: Healthcare, Research, and Technology.

Want to see what other hedge funds are holding BEAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioTelemetry Inc (NASDAQ:BEAT).

Institutional Ownership by Quarter for BioTelemetry (NASDAQ:BEAT)

Receive News & Ratings for BioTelemetry Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply